NCT00000314

Brief Summary

The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Sep 1994

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1994

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 1999

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 1999

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 20, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 21, 1999

Completed
Last Updated

January 18, 2017

Status Verified

December 1, 2002

Enrollment Period

4.9 years

First QC Date

September 20, 1999

Last Update Submit

January 17, 2017

Conditions

Cocaine-Related Disorders

Keywords

cocaine dependence

Outcome Measures

Primary Outcomes (2)

  • Drug use

  • Hospitalization, arrests, jail, employment, psychiataric symptoms

Interventions

M-CPPDRUG

Eligibility Criteria

Age25 Years - 50 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Please contact site for information.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

VA Medical Center

Brooklyn, New York, 11209, United States

Location

Related Publications (1)

  • Ulmann G, Jouinot A, Tlemsani C, Curis E, Kousignian I, Neveux N, Durand JP, Goldwasser F, Cynober L, De Bandt JP. Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer. Ann Nutr Metab. 2019;75(4):223-230. doi: 10.1159/000504874. Epub 2019 Dec 19.

    PMID: 31865308DERIVED

MeSH Terms

Conditions

Cocaine-Related Disorders

Interventions

1-(3-chlorophenyl)piperazine

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Laure Buydens-Branchey, M.D.

    VA Medical Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

September 20, 1999

First Posted

September 21, 1999

Study Start

September 1, 1994

Primary Completion

August 1, 1999

Study Completion

August 1, 1999

Last Updated

January 18, 2017

Record last verified: 2002-12

Locations

US(1)